Key result
Enhanced external counterpulsation (EECP) should be limited to patients with debilitating refractory angina pectoris who are not candidates for revascularisation and remain symptomatic on maximal therapy.
Why the study?
Does enhanced external counterpulsation improve symptoms in patients with refractory angina pectoris?
Does enhanced external counterpulsation improve symptoms in patients with refractory angina pectoris?
EECP may be considered for patients with debilitating refractory angina who are not candidates for revascularization and remain symptomatic on maximal medical therapy.
Supports targeted EECP use in refractory angina; leaves open broader efficacy without randomized confirmation.
Enhanced external counterpulsation (EECP) is a non-invasive outpatient treatment used for angina pectoris. In patients with intractable angina refractory to aggressive surgical and medical treatment, several novel strategies are considered including EECP, transmural laser revascularisation, and spinal cord stimulation. EECP produces an acute haemodynamic effect that is presumed to be similar to that produced by the invasive intra-aortic balloon pump. By applying a series of compressive cuffs sequentially from the calves to the thigh muscles upon diastole and rapidly deflating the cuffs in early systole, an increase in diastolic and decrease in systolic pressure is created. Although data indicate improvement in angina in patients undergoing EECP, the role of EECP in the treatment of angina pectoris has not yet been well defined. At present, EECP use should be limited to patients with debilitating (functional class III and IV) refractory angina pectoris who are not candidates for revascularisation, are symptomatic despite being on maximal antianginal pharmacotherapy, and have no contraindications to EECP use.
No takes yet. Share an insight, caveat, or question.
R M Sinvhal (2003) conducted a review in Refractory angina pectoris. Enhanced external counterpulsation (EECP) was evaluated. Enhanced external counterpulsation (EECP) should be limited to patients with debilitating refractory angina pectoris who are not candidates for revascularisation and remain symptomatic on maximal therapy.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: